Download the Whitepaper: Carragelose® Eye Drops A Novel Approach to Dry Eye Disease Treatment This whitepaper presents an in-depth analysis of Carragelose®, a preservative-free ophthalmic solution designed to address the challenges associated with Dry Eye Disease (DED). With its unique mucoadhesive and hydrating properties, Carragelose® offers an alternative to conventional treatments by enhancing tear film stability and prolonging moisture retention. Key Topics Covered: The molecular composition and mechanism of action of Carragelose®. Comparative in-vitro and clinical data demonstrating its efficacy. Insights into the role of mucoadhesion in ocular surface protection. A discussion on how it compares to traditional hyaluronic acid-based formulations. Access the Full Whitepaper Complete the form below to download the whitepaper and explore the latest advancements in Dry Eye Disease treatment. Unither Pharmaceuticals’ Acquisition of Carragelose® Unither Pharmaceuticals has incorporated Carragelose® into its ophthalmic product portfolio, reinforcing its expertise in drug delivery technologies. This acquisition aligns with Unither’s broader commitment to advancing pharmaceutical innovations in ophthalmology, ensuring continued development and accessibility of Carragelose® formulations. Read more about this acquisition : Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division Marinomed Biotech AG: approves sale of Carragelose division
